Addex Therapeutics Statistics
Want to see CH:ADXN full AI Analyst Report?
Addex Therapeutics (ADXN) Stock Statistics & Valuation Metrics
Total Valuation
Addex Therapeutics has a market cap or net worth of CHF 3.52M. The enterprise value is CHF 4.26M.
- Market Cap
- CHF 3.52M
- Enterprise Value
- CHF 4.26M
Share Statistics
Addex Therapeutics has 311,654,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 311,654,500
- Owned by Insiders
- ―
- Owned by Institutions
- 0.04%
Financial Efficiency
Addex Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -54.47%.
- Return on Equity (ROE)
- -1.41
- Return on Assets (ROA)
- -1.06
- Return on Invested Capital (ROIC)
- -54.47%
- Return on Capital Employed (ROCE)
- -0.55
- Revenue Per Employee
- 57.67K
- Profits Per Employee
- -2.24M
- Employee Count
- 3
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Addex Therapeutics is -0.59. Addex Therapeutics’s PEG ratio is -0.02.
- PE Ratio
- -0.59
- PS Ratio
- 55.65
- PB Ratio
- 2.53
- Price to FCF
- -1.47
- Price to Operating Cash Flow
- -2.02
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Addex Therapeutics had revenue of 173.00K and earned -6.73M in profits. Earnings per share was -0.06.
- Revenue
- 173.00K
- Gross Profit
- 164.39K
- Operating Income
- -2.81M
- Pretax Income
- -6.84M
- Net Income
- -6.73M
- EBITDA
- -2.81M
- Earnings Per Share (EPS)
- -0.06
Cash Flow
In the last 12 months, operating cash flow was -2.39M and capital expenditures -5, giving a free cash flow of -2.39M billion.
- Operating Cash Flow
- -2.39M
- Free Cash Flow
- -2.39M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -67.93%
- Earnings Yield
- -142.68%
Stock Price Statistics
- Beta
- 0.72
- 52-Week Price Change
- -52.63%
- 50-Day Moving Average
- 0.02
- 200-Day Moving Average
- 0.04
- Relative Strength Index (RSI)
- 94.18
- Average Volume (3m)
- 1.55M
Important Dates
Addex Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Addex Therapeutics as a current ratio of 1.40, with Debt / Equity ratio of 0.73%
- Current Ratio
- 1.40
- Quick Ratio
- 1.40
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.57
- Interest Coverage Ratio
- -175.94
Taxes
In the past 12 months, Addex Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Addex Therapeutics EV to EBITDA ratio is -0.82, with an EV/FCF ratio of -1.18.
- EV to Sales
- 44.73
- EV to EBITDA
- -0.82
- EV to Free Cash Flow
- -1.18
- EV to Operating Cash Flow
- -1.18
Balance Sheet
Addex Therapeutics has CHF 767.33K in cash and marketable securities with CHF 77.50K in debt, giving a net cash position of CHF 689.83K billion.
- Cash & Marketable Securities
- CHF 767.33K
- Total Debt
- CHF 77.50K
- Net Cash
- CHF 689.83K
- Net Cash Per Share
- CHF 0.00
- Tangible Book Value Per Share
- CHF 0.01
Margins
Gross margin is 41.19%, with operating margin of -4115.07%, and net profit margin of -10874.58%.
- Gross Margin
- 41.19%
- Operating Margin
- -4115.07%
- Pretax Margin
- -10867.08%
- Net Profit Margin
- -10874.58%
- EBITDA Margin
- -5446.68%
- EBIT Margin
- -5508.56%
Analyst Forecast
The average price target for Addex Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -50.34%
- EPS Growth Forecast
- 4.75%
Scores
- Smart Score
- 0
- AI Score
- 48

